Buy or sell Axcella stock pre IPO via an EquityZen fund
Axcella is a biotechnology company providing therapeutics development solutions.
About Axcella Stock
Axcella Health is pioneering revolutionary new medicines with a focus on amino acid homeostasis. The company has discovered more than 2,000 diseases with amino acid imbalances and developed a systems pharmacology approach to restore health at the cellular level. Axcella’s proprietary platform is clinically validated across several indication areas, with clinical-stage candidates in muscle, neurodegenerative and liver conditions. Axcella is led by a team with a strong track record of leaving a lasting impact on the therapeutic landscape through the development of novel products.
Senior Vice President and Chief Medical Officer
President and Chief Executive Officer
President of R&D and Chief Scientific Officer
Geoffrey von Maltzahn
Principal Research Fellow